Abeona Therapeutics (NASDAQ:ABEO) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Tuesday.
A number of other equities research analysts have also weighed in on ABEO. Zacks Investment Research raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, February 6th. ValuEngine lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, February 5th. Mizuho reissued a “buy” rating and set a $17.00 target price on shares of Abeona Therapeutics in a research note on Monday, December 10th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Abeona Therapeutics in a report on Friday, December 7th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $36.00 price objective on shares of Abeona Therapeutics in a report on Thursday, December 6th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. Abeona Therapeutics currently has an average rating of “Buy” and a consensus target price of $26.88.
Shares of NASDAQ:ABEO opened at $6.59 on Tuesday. The company has a market capitalization of $320.27 million, a PE ratio of -9.98 and a beta of 1.94. Abeona Therapeutics has a 12 month low of $6.26 and a 12 month high of $22.00.
About Abeona Therapeutics
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Further Reading: What is the price-sales ratio?
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.